The Ultimate Biopharma Dealmakers Report for Alliances and M&As, Second Edition 2016–2019
Alongside venture capital and public market investment, biopharmaceutical company alliances remain key sources of capital for advancing drug discovery and development efforts across the industry. Since the beginning of July 2016 through the end of the second quarter of 2019, biopharma companies have inked more than 500 alliances where potential deal value of >$50 million was disclosed.
In aggregate, those deals were worth nearly $34 billion in guaranteed upfront alliance payments. Total possible cumulative payments under these deals exceed $281 billion.
Besides alliances, pipeline projects and revenue from acquired biopharma companies continue to be the lifeblood of the global biopharma industry.
During the same three-year timeframe, 122 biopharma company acquisitions with disclosed upfront payments were worth nearly $383 billion in guaranteed acquisition payments, led by Takeda Pharmaceutical Co.’s acquisition of Shire, Bristol-Myers Squibb Co.’s acquisition of Celgene, and AbbVie’s recently announced acquisition of Allergan. Total potential payments for the entire cohort of deals reaches nearly $413 billion over the three-year span.
Dive into the details of these game-changing deals and what they indicate for the future of the biopharma industry.
What's Inside:
- Biopharma Alliance Trends
- Biopharma M&A Trends
- Top 10 Alliances by upfront deal value
- Top 16 M&A by upfront deal value